Vivimed Life Sciences Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Vivimed Life Sciences Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $5.8M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Vivimed Life Sciences Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $5.8M Trade | TransData Nexus

Vivimed Life Sciences Private Limited

Indian Pharmaceutical Exporter · Analgesics & Antipyretics Specialist · $5.8M Total Trade · DGFT Verified

Vivimed Life Sciences Private Limited is an Indian pharmaceutical exporter with a total trade value of $5.8M across 3 products in 3 therapeutic categories. Based on 116 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ibuprofen ($3.3M), Clindamycin ($1.6M), Nystatin ($950.0K).

Vivimed Life Sciences Private Limited — Export Portfolio & Destination Treemap

Vivimed Life Sciences Private Limited pharmaceutical export portfolio — 3 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Vivimed Life Sciences Private Limited? — Company Overview & Market Position

Vivimed Life Sciences Private Limited, established on February 20, 2017, is a private limited company incorporated under the Companies Act, 2013, with its registered office at 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, Maharashtra, India. The company operates in the manufacturing sector, focusing on pharmaceutical formulations, and is classified as a non-government company. Its Corporate Identification Number (CIN) is U24304MH2017PTC348859. Vivimed Life Sciences is a wholly owned subsidiary of Strides Pharma Science Limited, following Strides' acquisition of the remaining 50% stake from Vivimed Labs Limited on January 29, 2019. The company has an authorized share capital of ₹300 million and a paid-up capital of ₹282.67 million. As of the latest available data, Vivimed Life Sciences employs approximately 289 professionals. The company's official website is not specified in the available sources.

What Does Vivimed Life Sciences Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ibuprofen$3.3M 2Clindamycin

Product Portfolio — Top 3 by Export Value

Vivimed Life Sciences Private Limited exports 3 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ibuprofen	Analgesics & Antipyretics	$3.3M	66	0.6%	11
2	Clindamycin	Antibiotics	$1.6M	31	1.7%	11
3	Nystatin	Antifungals	$950.0K	19	1.8%	6

Vivimed Life Sciences Private Limited exports 3 pharmaceutical products across 3 therapeutic categories with a total export value of $5.8M. The top category is Analgesics & Antipyretics (56.9% of portfolio), followed by Antibiotics (26.7%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Vivimed Life Sciences Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Vivimed Life Sciences operates manufacturing facilities in Alathur, Tamil Nadu, and Banjara Hills, Hyderabad, Telangana. The Alathur plant is located at Plot No. 101, 102, 107 & 108, SIDCO Pharmaceutical Complex, Alathur, Kanchipuram District, Tamil Nadu 603110, India. The Hyderabad facility is situated at 8-2120/86/9/A/1 & 12, Anil Athmaja Housing Society, Road No. 2, Banjara Hills, Hyderabad, Telangana 500034, India. Specific details regarding the manufacturing capacities and specializations of these facilities are not available in the provided sources.

3Key Leadership

The key leadership team at Vivimed Life Sciences Private Limited includes:

Vikesh Kumar: Director since February 20, 2019.

Venkata Seetharama Raju Pakalapati: Director since April 25, 2024.

Umesh Pralhadrao Kale: Director since February 20, 2019.

The roles of Chief Executive Officer (CEO) and Chief Financial Officer (CFO) are not specified in the available sources.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Vivimed Life Sciences Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Vivimed Life Sciences Private Limited has engaged in the U.S. market through its manufacturing facility in Alathur, Tamil Nadu. In May 2019, the company voluntarily recalled 19 lots of Losartan Potassium Tablets USP due to the detection of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA), a potential carcinogen, above the FDA's acceptable exposure limit. This recall indicates the company's compliance with U.S. regulatory standards. Specific information regarding the company's presence in the European Union (EU), United Kingdom (UK), Australia, and Japan, including regulatory filings, approvals, and market access status, is not available in the provided sources.

2Emerging Markets

Vivimed Life Sciences Private Limited has demonstrated a presence in emerging markets, particularly in Africa, Latin America, and Southeast Asia. The company's export data indicates shipments to countries such as Kenya and South Africa, suggesting engagement in the African market. Additionally, the company's manufacturing facilities in Alathur, Tamil Nadu, and Banjara Hills, Hyderabad, Telangana, may facilitate access to Southeast Asian markets. Specific details regarding WHO prequalification or other certifications enabling access to these markets are not available in the provided sources.

3Geographic Strategy

Vivimed Life Sciences Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Vivimed Life Sciences Private Limited has engaged with the U.S. Food and Drug Administration (FDA) through its manufacturing facility in Alathur, Tamil Nadu. In May 2019, the company voluntarily recalled 19 lots of Losartan Potassium Tablets USP due to the detection of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA), a potential carcinogen, above the FDA's acceptable exposure limit. This recall indicates the company's compliance with FDA regulations. Specific details regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not available in the provided sources.

2WHO & EU GMP

Specific information regarding WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status for Vivimed Life Sciences Private Limited is not available in the provided sources. These certifications are crucial for market access in various regions and for ensuring product quality and safety.

3CDSCO & Indian Regulatory

Vivimed Life Sciences Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Vivimed Life Sciences Private Limited operates in the pharmaceutical industry, focusing on finished pharmaceutical formulations. The company's top competitors in overlapping categories include major pharmaceutical companies that produce analgesics, antibiotics, and antifungals. While specific market share comparisons are not available in the provided sources, Vivimed's export data indicates a diversified export strategy, with shipments to various countries, including the United States, Kenya, and South Africa. This suggests that Vivimed competes with both domestic and international players in these markets.

2Key Differentiators

Vivimed Life Sciences Private Limited's key differentiators include its manufacturing facilities in Alathur, Tamil Nadu, and Banjara Hills, Hyderabad, Telangana, which enable it to serve both domestic and international markets. The company's export data indicates shipments to countries such as the United States, Kenya, and South Africa, reflecting a diversified export strategy. Additionally, the company's proactive approach to regulatory compliance, as demonstrated by the voluntary recall of Losartan Potassium Tablets USP in May 2019, underscores its commitment to product safety and quality.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Vivimed Life Sciences Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Vivimed Life Sciences Private Limited has demonstrated a consistent track record in its export activities, with 116 shipments recorded between 2022 and 2026, totaling an export value of $5.8 million USD. The company's top three exported products—Ibuprofen, Clindamycin, and Nystatin—account for 100% of its export portfolio, indicating a focused product strategy. The company's export data indicates shipments to various countries, including the United States, Kenya, and South Africa, reflecting a diversified export strategy.

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Vivimed Life Sciences Private Limited

How many pharmaceutical products does Vivimed Life Sciences Private Limited export from India?

Vivimed Life Sciences Private Limited exports 3 pharmaceutical products across 3 therapeutic categories. The top exports are Ibuprofen ($3.3M), Clindamycin ($1.6M), Nystatin ($950.0K). Total export value is $5.8M.

What is Vivimed Life Sciences Private Limited's total pharmaceutical export value?

Vivimed Life Sciences Private Limited's total pharmaceutical export value is $5.8M, based on 116 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Vivimed Life Sciences Private Limited cover?

Vivimed Life Sciences Private Limited exports across 3 therapeutic categories. The largest are Analgesics & Antipyretics (56.9%, 1 products), Antibiotics (26.7%, 1 products), Antifungals (16.4%, 1 products).

Get Full Vivimed Life Sciences Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.